Molecular crosstalk between adhesion receptors and proteolytic cascades in vascular remodelling

Thrombosis and Haemostasis

Volumn 78, Issue 1, 1997, Pages 88-95

  Preissner, K T ^a,b   May, A E ^a   Wohn, K D ^a   Germer, M ^a   Kanse, S M ^a  

^a MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^b KERCKHOFF HEART CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; CELL RECEPTOR; INTEGRIN; OSTEONECTIN; PLASMINOGEN ACTIVATOR; PROTEINASE; SCLEROPROTEIN; VITRONECTIN; VITRONECTIN RECEPTOR;

ANGIOGENESIS; APOPTOSIS; ATHEROGENESIS; BINDING AFFINITY; BLOOD VESSEL INJURY; CELL ADHESION; CELL INTERACTION; CELL MIGRATION; CONFERENCE PAPER; HUMAN; HUMAN CELL; INFLAMMATION; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION;

EID: 0030877824     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657507     Document Type: Conference Paper

References (114)

1. Folkman J, D'Amore PA. Blood vessel formation: What is its molecular basis? Cell 1996; 87:1153-5.
2. Breier G, Risau W. The role of vascular endothelial growth factor in blood vessel formation. Trends Cell Biol 1996; 6:454-6.
3. Fässler R, Georges-Labouesse E, Hirsch E. Genetic analysis of integrin function in mice. Curr Opin Cell Biol 1996; 8:641-6.
4. Woods A, Couchman JR. Signaling from the matrix to the cytoskeleton-role of cell surface proteoglycans in matrix assembly. Kidney Intern 1996; 49:64-7.
5. Couchman JR, Woods A. Syndecans, signaling, and cell adhesion. J Cell Biochem 1996; 61:578-84.
6. Humphries MJ. The molecular basis and specificity of integrin-ligand interactions. J Cell Sci 1990; 97:585-92.
7. Lafrenie RM, Yamada KM. Intgrin-dependent signal transduction. J Cell Biochem 1996; 61:543-53.
8. Ruoslahti E. Integrin signaling and matrix assembly. Tumor Biol 1996; 17:117-24.
9. Hynes RO. Integrins:Versatility, modulation, and signaling in cell adhesion. Cell 1992; 69:11-25.
10. Ingber DE, Folkman J. How does extracellular matrix control capillary morphogenesis? Cell 1989; 58:803-5.
11. Felding-Habermann B, Cheresh DA. Vitronectin and its receptors. Curr Opin Cell Biol 1993; 5:864-8.
12. Davis CM, Danehower SC, Laurenza A, Molony JL. Identification of a role of the vitronectin receptor and protein kinase C in the induction of endothelial cell vascular formation. J Cell Biol 1993; 51:206-18.
13. Casaroli Marano RP, Preissner KT, Vilaro S. Fibronectin, laminin, vitronectin and their receptors at newly-formed capillaries in proliferative diabetic retinopathy. Exp Eye Res 1995; 60:5-17.
14. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79:1157-64.
15. Meredith JE, Fazeli B, Schwartz MA. The extracellular matrix as a cell survival factor. Mol Biol Cell 1993; 4:953-61.
16. Re F, Zanetti A, Sironi M, Polemarutti N, Lanfrancone L, Dejana E, Colotta F. Inhibition of anchorage-dependent cell spreading triggers apoptosis in cultured human endothelial cells. J Cell Biol 1994; 127:537-46.
17. Fang F, Orend G, Watanabe N, Hunter T, Ruoslahti E. Dependence of cyclic E-CDK2 kinase activity on cell anchorage. Science 1996; 271:499-502.
18. Strömblad S, Becker JC, Yebra M, Brooks PC, Cheresh DA. Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cll integrin αvβ3 during angiogenesis. J Clin Invest 1996; 98:426-33.
19. Senger DR. Molecular framework for angiogenesis. A complex web of interactions between extravasated plasma proteins and endothelial cell proteins induced by angiogenic cytokines. Am J Path 1996; 149:1-7.
20. Davis GE. Affinity of integrins for damaged extracellular matrix -αvβ3 binds to denatured collagen type-I through RGD sites. Biochem Biophys Res Commun 1992; 182:1025-31.
21. Koyama H, Raines EW, Bornfeldt KE, Roberts JM, Ross R. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell 1996; 87:1069-78.
22. Miyamoto S, Akiyama SK, Yamada KM. Synergistic roles for receptor occupancy and aggregation in integrin transmembrane function. Science 1995; 267:883-5.
23. Preissner KT. Structure and biological role of vitronectin. Ann Rev Cell Biol 1991; 7:275-310.
24. Tomasini BR, Mosher DF. Vitronectin. Prog Hemostas Thromb 1990; 10:269-305.
25. Hess S, Kanse SM, Kost C, Preissner KT. The versatility of adhesion receptor ligands in haemostasis: morpho-regulatory functions of vitronectin. Thromb Haemostas 1995; 74:258-65.
26. Lim BL, Reid KBM, Ghebrehiwet B, Peerschke EIB, Leight LAE, Preissner KT. The binding protein for globular heads of complement C1q, gC1qR. Functional expression and characterization as a novel vitronectin binding factor. J Biol Chem 1996; 271:26739-44.
27. Zanetti A, Conforti G, Hess S, Martinpadura I, Ghibaudi E, Preissner KT, Dejana E. Clustering of vitronectin and RGD peptides on microspheres leads to engagement of integrins on the luminal aspect of endothelial cell membrane. Blood 1994; 84: 1116-23.
28. Bhattacharya S, Fu C, Bhattacharya J, Greenberg S. Soluble ligands of the avβ3 integrin mediate enhanced tyrosine phosphorylation of multiple proteins in adherent bovine pulmonary artery endothelial cells. J Biol Chem 1995; 28:16781-7.
29. Sage EH, Bornstein P. Extracellular proteins that modulate cell-matrix interactions:sparc, tenascin, and thrombospondin. J Biol Chem 1991; 266:14831-4.
30. Iruela-Arispe ML, Bornstein P, Sage H. Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. Proc Natl Acad Sci USA 1991; 88:5026-30.
31. Lahav J. The functions of thrombospondin and its involvement in physiology and pathophysiology. Biochim Biophys Acta 1993; 1182:1-14.
32. Schultz-Cherry S, Ribeiro S, Gentry L, Murphy-Ullrich JE. Thrombospondin binds and activates the small and large forms of latent transforming growth factor-β in a chemically defined system. J Biol Chem 1994; 269:26775-82.
33. Lane TF, Iruela-Arispe ML, Johnson RS, Sage EH. SPARC is a source of copper-binding peptides that stimulate angiogenesis. J Cell Biol 1994; 125:929-43.
34. Sriramarao P, Mendler M, Bourdon MA. Endothelial cell attachment and spreading on human tenascin is mediated by α2β1 and αVβ3 integrins. J Cell Sci 1993; 105:1001-12.
35. Chung CY, Erickson HP. Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-c. J Cell Biol 1994; 126:539-48.
36. Rosenblatt S, Bassuk JA, Alpers CE, Sage EH, Timpl R, Preissner KT. Differential modulation of cell adhesion by interaction between adhesive and counteradhesive proteins: Characterization of the binding of vitronectin to osteonectin (BM40, SPARC). Biochem J, in press.
37. Dellian M, Witwer BP, Salehi HA, Yuan F, Jain RK. Quantitation and physiological characterization of angiogenic vessels in mice. Am J Pathol 1996; 149:59-71.
38. Chen WT. Membrane proteases:roles in tissue remodeling and tumour invasion. Curr Opin Cell Biol 1992; 4:802-9.
39. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 1996; 7:728-35.
40. Mignatti P, Tsuboi R, Robbins E, Rifkin DB. In vitro angiogenesis on the human amniotic membrane: Requirement for basic fibroblast growth factor-induced proteinases. J Cell Biol 1989; 108:671-82.
41. Mimuro J, Loskutoff DJ. Binding of type 1 plasminogen activator inhibitor to the extracellular matrix of cultured bovine endothelial cells. J Biol Chem 1989; 264:5058-63.
42. Preissner KT, Grulich-Henn J, Ehrlich HJ, Declerck P, Justus C, Collen D, Pannekoek H, Müller-Bergbaus G. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin. J Biol Chem 1990; 265:18490-8.
43. Rovelli G, Stone SR, Preissner KT, Monard D. Specific interaction of vitronectin with the cell-secreted protease inhibitor glia-derived nexin (GDN) and the GDN-thrombin complex. Eur J Biochem 1990; 192:797-803.
44. Baker JB, Low DA, Simmer RL, Cunningham DD. Protease nexin: a cellular component that links thrombin and plasminogen activator and mediates their binding to cells. Cell 1980; 21:37-45.
45. Mackay AR, Ballin M, Pellina MD, Farina AR, Nason AM, Hartzler JL, Thorgeirsson UP. Effect of phorbol ester and cytokines on matrix metalloproteinase and tissue inhibitor of metalloproteinase expression in tumor and normal cell lines. Invasion Metastasis 1992; 12:168-84.
46. Mattsson E, Clowes AW. Current concepts in restenosis following balloon angioplasty. Trends Cardiovasc Med 1995; 5:200-4.
47. Bu G, Warshawsky I, Schwartz AL. Cellular receptors for the plasminogen activators. Blood 1994; 83:3427-36.
48. Korner G, Bjornsson TD, Vlodavsky I. Extracellular matrix produced by cultured comeal and aortic endothelial cells contains active tissue-type and urokinase-type plaminogen activators. J Cell Physiol 1993; 154:456-65.
49. Quigley JP, Gold LI, Schwimmer R, Sullivan LM. Limited cleavage of cellular fibronectin by plasminogen activator purified from transformed cells. Proc Natl Acad Sci USA 1987; 84: 2776-80.
50. Moller LB. Structure and function of the urokinase receptor. Blood Coagul Fibrin 1993; 4:293-303.
51. Lund LR, Romer J, Ronne E, Ellis V, Blasi F, Dano K. Urokinase-receptor biosynthesis, messenger-RNA level and gene transcription are increased by transforming growth factor β1 in human A549 lung-carcinoma cells. EMBO J 1991; 10:3399-407.
52. Ossowski L, Clunie G, Masucci M, Blasi F. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Biol 1993; 115:1107-12.
53. Montesano R, Pepper MS, Möhle-Steinlein U, Risau W, Wagner EF, Orci L. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell 1990; 62:435-45.
54. Moser TL, Enghild JJ, Pizzo SV, Stack MS. The extracellular matrix proteins laminin and fibronectin contain binding domains for human plasminogen and tissue plasminogen activator. J Biol Chem 1993; 268:18917-23.
55. Cesarman GM, Guevara CA, Hajjar KA. An endothelial cell receptor for plasminogen tissue-plasminogen activator (t-pa). 2. annexin ii-mediated enhancement of t-pa-dependent plasminogen activation. J Biol Chem 1994; 269:21198-203.
56. Miles LA, Dahlberg CM, Plescia J, Felez J, Kato K, Plow EF. Role of cell-surface lysines in plasminogen binding to cells: Identification of α-enolase as a candidate plasminogen receptor. Biochemistry 1991; 30:1682-91.
57. Vaheri A, Stephens RW, Salonen E-M, Pöllänen J, Tapiovaara H. Plasminogen activation at the cell surface-matrix interface. Cell Diff Dev 1990; 32:255-62.
58. Kost C, Benner K, Stockmann A, Linder D, Preissner KT. Limited plasmin proteolysis of vitronectin: characterization of the adhesion protein as morpho-regulatory and angiostatin-binding factor. Eur J Biochem 1996; 236:682-8.
59. Bugge TH, Flick MJ, Daugherty CC, Degen JL. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Develop 1995; 9:794-807.
60. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79:315-28.
61. Miles LA, Plow EF. Lp(a) - an interloper into the fibrinolytic system. Thromb Haemost 1990; 63:331-5.
62. Orth K, Madison LE, Gething M, Sambrook JF, Herz J. Complexes of tissue-type plasminogen activator with PAI-1 are internalized by means of the low density lipoprotein receptor-related protein/α2-macroglobulin receptor. Proc Natl Acad Sci USA 1992; 89:7422-6.
63. Hoyer-Hansen G, Ronne E, Solberg H, Behrendt N, Ploug M, Lund LR, Ellis V, Dano K. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem 1992; 267:18224-9.
64. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature 1994; 370:460-2.
65. Brown E, Hooper L, Ho T, Gresham H. Integrin-associated protein: A 50-kD plasma membrane antigen physically and functionally associated with integrins. J Cell Biol 1990; 111: 2785-94.
66. Yebra M, Parry GCN, Stromblad S, Mackman N, Rosenberg S, Mueller BM, Cheresh DA. Requirement of receptor-bound urokinase-type plasminogen activator for integrin αvβ5-directed cell migration. J Biol Chem 1996; 271:29393-9.
67. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, Chapman HA. Regulation of integrin function by the urokinase receptor. Science 1996; 273:1551-5.
68. Pöllänen J, Hedman K, Nielsen LS, Dano K, Vaheri A. Ultra-structural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J Cell Biol 1988; 106:87-95.
69. Pöllänen J, Saksela O, Salonen E-M, Andreasen P, Nielsen L, Dano K, Vaheri A. Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol 1987; 104: 1085-96.
70. Ciambrone GJ, McKeown-Longo PJ. Plasminogen activator inhibitor type I stabilizes vitronectin-dependent adhesions in HT-1080 cells. J Cell Biol 1990; 111:2183-95.
71. Ciambrone GJ, McKeown-Longo PJ. Vitronectin regulates the synthesis and localization of urokinase-type plasminogen activator in HT-1080 cells. J Biol Chem 1992; 267:13617-22.
72. Pöllänen J, Stephens RW, Vaheri A. Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 1991; 57:273-328.
73. Mignatti P, Mazzieri R, Rifkin DB. Expression of the urokinase receptor in vascular endothelial cells is stimulated by basic fibroblast growth-factor. J Cell Biol 1991; 113:1193-201.
74. Mandriota SJ, Seghezzi G, Vassalli JD, Ferrara N, Wasi S, Mazzieri R, Mignatti P, Pepper MS. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem 1995; 270:9709-16.
75. Pepper MS, Sappino AP, Stocklin R, Orci L, Vassalli JD. Upregulation of urokinase receptor expression on migrating endothelial cells. J Cell Biol 1993; 122:673-84.
76. Estreicher A, Mühlhauser J, Carpentier J-L, Orci L, Vassalli J-D. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 1990; 111:783-92.
77. Gyetko MR, Todd III RF, Wilkinson CC, Sitrin RG. The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest 1994; 93:1380-7.
78. Waltz DA, Sailor LZ, Chapman HA. Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors. J Clin Invest 1993; 91:1541-52.
79. Kanse SM, Kost C, Wilhelm OG, Andreasen PA, Preissner KT. The urokinase receptor is a major vitronectin binding protein on endothelial cells. Exp Cell Res 1996; 224:344-53.
80. Waltz DA, Chapman HA. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem 1994; 269:14746-50.
81. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 1996; 134:1563-71.
82. Preissner KT. Vitronectin as link between protease cascades and cell adhesion in haemostasis, in: Vascular Control of Hemostasis, van Hinsbergh VWM (ed). Amsterdam: Harwood Academic 1996; pp 169-86.
83. Moser TL, Enghild JJ, Pizzo SV, Stack MS. Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA depnedent adhesion of U937 cells. Biochem J 1995; 307:867-73.
84. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994; 269: 32380-8.
85. Brooks PC, Strömblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA. Localization of matrix metalloproteinase MMP-2 to the surface of invasisve cells by interaction with integrin αvβ3. Cell 1996; 85:683-93.
86. Piali L, Hammel PM, Uherek C, Bachmann F, Gisler RH, Dunon D, Imhof BA. CD31/PECAM-1 is a ligand for αvβ3-integrin involved in adhesion of leukocytes to endotheliu. J Cell Biol 1995; 130:451-60.
87. Kjoller L, Kanse SM, Kirkegaard T, Rodenburg KW, Ronne E, Goodman SL, Preissner KT, Ossowski L, Andreasen PA. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res, in press.
88. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell megration by blocking integrin αvβ3 binding to vitronectin. Nature 1996; 383:441-3.
89. Jänicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, Gössner W, Graeff H. Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 1990; 4:69-78.
90. Duffy MJ, Reilly D, Mcdermott E, Ohiggins N, Fennelly JJ, Andreasen PA. Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer 1994; 74:2276-80.
91. Carmeliet P, Collen D. Gene targeting and gene transfer studies of the plasminogen/plasmin syseem:implications in thrombosis, hemostasis, neointima formation, and atherosclerosis. FASEB J 1995; 9:934-8.
92. Carmeliet P, Collen D. Role of the plasminogen/plasmin system in thrombosis, hemostasis, restenosis and atherosclerosis. Trends Cardiovasc Med 1995; 5:117-22.
93. Zheng X, Saunders TL, Camper SA, Samuelson LC, Ginsburg D. Vitronectin is not essential for normal mammalian development and fertility. Proc Natl Acad Sci USA 1995; 92:12426-30.
94. Wohn KD, Kanse SM, Deutsch V, Schmidt T, Eldor A, Preissner KT. The urokinase receptor (CD87) is expressed in cells of the megakaryoblastic lineage. Thromb Haemost, in press.
95. Leven RM, Tablin F. Extracellular matrix stimulation of guinea pig megakaryocyte proplatelet formation in vitro is mediated through the vitronectin receptor. Exp Hematol 1992; 20:1316-22.
96. Leven RM. Differential regulation of integrin-mediated proplatelet formation and megakaryocyte spreading. J Cell Physiol 1995; 163:597-607.
97. Cao DR, Mizukami IF, Garniwagner BA, Kindzelskii AL, Todd RF, Boxer LA, Petty HR. Human urokinase-type plasminogen activator primes neutrophils for superoxide anion release -possible roles of complement receptor type 3 and calcium. J Immunol 1995; 154:1817-29.
98. Dumler I, Petri T, Schleuning W-D. Interaction of urokinase-type plasminogenactivator (u-PA) with its cellular receptor (u-PAR) induces phosphorylation on tyrosine of a 38 kDA protein. FEBS Lett 1993; 322:37-40.
99. Petty HR, Todd RF. Integrins as promiscuous signal transduction devices. Immunol Today 1996; 17:209-12.
100. Bohuslav J, Horejsi V, Hansmann C, Stöckl J, Weidle UH, Majdic O, Bartke I, Knapp W, Stockinger H. Urokinase plasminogen activator receptor, β2-integrins, and scr-kinases within a single receptor complex of human monocytes. J Exp Med 1995; 181:1381-90.
101. Higazi AA-R, Upson RH, Cohen RL, Manuppello J, Bognacki J, Henkin J, McCrae KR, Kounnas MZ, Strickland DK, Preissner KT, Lawler J, Cines DB. Interaction of single-chain urokinase with its receptor induces the appearance and disappearance of binding epitopes within the resultant complex for other cell surface proteins. Blood 1996; 88:542-51.
102. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 1996; 15:1572-82.
103. Sitrin RG, Todd RF, Petty HR, Brock TG, Shollenberger SB, Albrecht E, Gyetko MR. The urokinase receptor (CD87) facilitates CD11B/CD18-mediated adhesion of human monocytes. J Clin Invest 1996; 97:1942-51.
104. Meredith JE, Winitz S, McArthur Lewis J, Hess S, Ren X-D, Renshaw MW, Schwartz MA. The regulation of growth and intracellular signaling by integrins. Endocrinol Rev 1996; 17:207-20.
105. Min HY, Doyle LV, Vitt CR, Zandonella CL, Stratton-Thomas JR, Shuman MA, Rosenberg S. Urokinase receptor antangonist inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 1996; 56:2428-33.
106. Mitjans F, Sander D, Adan J, Sutter A, Martinez JM, Jäggle C, Moyano JM, Kreysch H, Piulats J, Goodman SL. An anti-av-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. J Cell Sci 1995; 108:2825-38.
107. Strömblad S, Cheresh DA. Cell adhesion and angiogenesis. Trends Cell Biol 1996; 6:462-7.
108. Montesano R. Regulation of angiogenesis in vitro. Eur J Clin Invest 1992; 22:504-15.
109. Hammes HP, Brownlee M, Joncyk A, Sutter A, Preissner KT. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nature Med 1996; 2:529-33.
110. Choi, Engel L, Callow AD, Sun S, Trachtenberg J, Santoro S, Ryan US. Inhibition of neointimal hyperplasia by blocking αvβ3 integrin with a small peptide antagonist GpenGRGDSPCA. J Vasc Surg 1994; 19:125-34.
111. Hynes RO, George EL, Georges EN, et al. Toward a genetic analysis of cell-matrix adhesion, in: Cold Spring Harbor Symposia on Quantitative Biology. CSH Press 1992; pp 249-57.
112. Preissner KT, Kanse SM. Protease receptors in the vasculature: Novel molecular links for the regulation of haemostasis and wound repair processes. Biomed Progr 1996; 9:22-7.
113. Panetti TS, McKeown-Longo PJ. The αvβ5 integrin receptor regulates receptor-mediated endocytosis of vitronectin. J Biol Chem 1993; 11492-5.
114. de Boer HC, Preissner KT, Bouma BN, de Groot PG. Internalization of vitronectin-thrombin-antithrombin complex by endothelial cells leads to deposition of the complex into the subendothelial matrix. J Biol Chem 1995; 30733-40.